Prothena | PRTA - Selling And Administration Expenses


Prothena reported $12.67M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
ALKERMES USD 264.59M 77.4M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Exelixis USD 139.6M 16.58M Mar/2026
Immunic USD 3.45M 451K Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Prothena USD 12.67M 5.02M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026
Xoma USD 11M 2.54M Jun/2024